Illustris Pharmaceuticals

Illustris Pharmaceuticals was a biotechnology company focused on the development of innovative topical therapies for dermatological and aesthetic applications. Based in San Francisco, the company leveraged a proprietary drug delivery platform to enhance the penetration and efficacy of active compounds in the skin. Its primary research efforts were directed toward skin rejuvenation, the treatment of photo-aged skin, and medical conditions such as actinic keratosis. The company's approach combined advanced molecular biology with clinical dermatology expertise to address unmet needs in skin health. In 2011, Illustris was acquired by Galderma, a move that allowed Galderma to expand its portfolio of aesthetic and corrective dermatology products.